Phase 3 Trial of ZALTRAP in Advanced Prostate Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee

Regeneron Pharmaceuticals, Inc. REGN today announced that the Phase 3 VENICE clinical trial evaluating the investigational agent ZALTRAP™ (aflibercept) in the first-line treatment of patients with androgen-independent (hormone-refractory) metastatic prostate cancer will continue to completion as planned, with no modifications due to efficacy or to safety concerns. This decision is based on the recommendation of an Independent Data Monitoring Committee (IDMC) following a planned interim analysis. Regeneron and Sanofi are collaborating in the development of ZALTRAP in oncology. Both Regeneron and Sanofi management and staff remain blinded to the interim study results. "We look forward to the final results of this trial next year in the hope of providing a new therapy for patients with metastatic prostate cancer," said George D. Yancopoulos, M.D., Ph.D., Chief Scientific Officer of Regeneron and President of Regeneron Research Laboratories.